Latest Ndis News

Bridge SaaS Limited reported a robust September quarter, buoyed by its majority-owned Brightside subsidiary's profitability and participant growth, while preparing to launch new NDIS services in New South Wales.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

McMillan Shakespeare Limited reported steady FY25 growth with Normalised UNPATA of $103.2 million and an 8.3% dividend yield, underpinned by digital innovation and strategic investments.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.

PeopleIN Limited posted a statutory net loss of $11.862 million for FY25, impacted by tough economic conditions and weather disruptions, while achieving significant cost savings and announcing a $6 million share buy-back.

nib Holdings reported a solid FY25 with underlying operating profit of $239.2 million and 3.2% policyholder growth, driven by digital innovation and operational efficiencies. The Group’s strategic focus on core health insurance and adjacent services sets the stage for continued momentum into FY26.

Bridge SaaS Limited reports steady cash flow and strategic focus on AI and robotics to transform disability care under the NDIS framework.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

Bridge SaaS Limited reports a 7% increase in NDIS participant numbers through its majority-owned Brightside, while advancing regional expansion and targeting cash flow positivity by refining operational efficiencies.

Control Bionics reports its strongest US revenue in years alongside Australia’s best quarter since 2022, propelled by new product launches and strategic investments.

Talius Group reported a solid March quarter with rising revenue, a strategic partnership with Lifestyle SA, and the rollout of its proprietary RTLS software, signaling strong momentum in aged care technology.

Bridge SaaS Limited has appointed Richard Gordon as CEO, signaling a strategic push to expand its footprint in the NDIS sector through acquisitions and technology innovation.